<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37150967</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1941-5923</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><PubDate><Year>2023</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>The American journal of case reports</Title><ISOAbbreviation>Am J Case Rep</ISOAbbreviation></Journal><ArticleTitle>Anti-PL12 Anti-Synthetase Syndrome and Amyotrophic Lateral Sclerosis: A Case Report of a Rare Comorbidity.</ArticleTitle><Pagination><StartPage>e939035</StartPage><MedlinePgn>e939035</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/AJCR.939035</ELocationID><Abstract><AbstractText>BACKGROUND Anti-PL-12 syndrome is a rare form of myositis. Amyotrophic lateral sclerosis (ALS) is the commonest of the motor neuron disorders. However, the 2 conditions have not been reported to occur together in a single individual. This case report describes a patient who was diagnosed with anti-PL-12 anti-synthetase syndrome and then subsequently was diagnosed with ALS. CASE REPORT A 55-year-old male patient had anti-PL-12 syndrome and ALS occurring together. The patient initially presented with musculoskeletal complaints and was diagnosed with anti-PL-12 syndrome. He later went on to develop shortness of breath. Neurophysiological testing subsequently confirmed ALS as the patient experienced worsening muscle weakness over a 2-year period. A muscle biopsy performed showed neurogenic and myopathic process. The patient eventually lost the ability to ambulate without mobility assistance and suffered cardiac arrest due to complications from ALS, specifically diaphragmatic dysfunction. CONCLUSIONS This case report represents the first documented case of a patient having both anit-PL-12 syndrome and ALS together. It has been suggested that having an autoimmune disease (AID) may increase the subsequent risk of developing ALS. Previous studies did not conduct evaluation to ascertain serological markers for AS antibodies. Lab tests were rechecked and revalidated multiple times in separate facilities for confirmation of results in case of initial lab error. This may suggest a common etiology for both anti-PL-12 syndrome and ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shamim</LastName><ForeName>Ejaz A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mid-Atlantic Permanente Medical Group, Rockville, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Mid-Atlantic Permanente Research Institute, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Melvin W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mid-Atlantic Permanente Medical Group, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Ivan Y</ForeName><Initials>IY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Mid-Atlantic Permanente Medical Group, Rockville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mid-Atlantic Permanente Medical Group, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Sharday N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Howard University Hospital, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagi</LastName><ForeName>Harpreet K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Medicine, West Virginia School of Osteopathic Medicine, Lewisburg, WV, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Case Rep</MedlineTA><NlmUniqueID>101489566</NlmUniqueID><ISSNLinking>1941-5923</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Conflict of interest:</b>
 None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37150967</ArticleId><ArticleId IdType="pmc">PMC10176515</ArticleId><ArticleId IdType="doi">10.12659/AJCR.939035</ArticleId><ArticleId IdType="pii">939035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, et al. Autoimmune disease preceding amyotrophic lateral sclerosis: An epidemiologic study. Neurology. 2013;81(14):1222&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C, Longinetti E, Larsson H, et al. Associations between autoimmune diseases and amyotrophic lateral sclerosis: A register-based study. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3&#x2013;4):211&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">33331190</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng CC, Chang SJ, Tsai WC, et al. Increased incidence of amyotrophic lateral sclerosis in polymyositis: A nationwide cohort study. Arthritis Care Res. 2017;69(8):1231&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">27723283</ArticleId></ArticleIdList></Reference><Reference><Citation>Parperis K. Increased amyotrophic lateral sclerosis in polymyositis: Comment on the article by Tseng et al. Arthritis Care Res (Hoboken) 2018;70(7):1119&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28973843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(7):344&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">1090839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng CC, Chang SJ, Tsai WC, et al. Reply. Arthritis Care Res (Hoboken) 2018;70(7):1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">28973839</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004913</ArticleId><ArticleId IdType="pubmed">29865091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gran TJ, Molberg O. The antisynthetase syndrome. In: Gran TJ, editor. Idiopathic inflammatory myopathies-recent developments. London: IntechOpen; 2011. pp. 65&#x2013;76.</Citation></Reference><Reference><Citation>Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Arthritis Rheumatol. 1980;23(8):881&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">7406938</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: Heterogeneity within the syndrome. PLoS One. 2013;8(4):e60442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616126</ArticleId><ArticleId IdType="pubmed">23573256</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas-Serrano J, Herrera-Bringas D, Mej&#xed;a M, et al. Prognostic factors in a cohort of antisynthetase syndrome (ASS) : Serological profile is associated with mortality in patients with interstitial lung disease (ILD) Clin Rheumatol. 2015;34(9):1563&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">26219488</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH. Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. CNS Drugs. 2011;25(1):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Marangi G, Conte A, et al. New ALS-related genes expand the spectrum paradigm of amyotrophic lateral sclerosis. Brain Pathol. 2016;26(2):266&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029226</ArticleId><ArticleId IdType="pubmed">26780671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantero V, Rigamonti A, Basso F, et al. When it rains it pours: Amyotrophic lateral sclerosis concealed with Isaac&#x2019;s syndrome. Neurol Sci. 2016;7(37):1181&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">26914588</ArticleId></ArticleIdList></Reference><Reference><Citation>Broccolini A, Mirabella M. Hereditary inclusion-body myopathies. Biochim Biophys Acta. 2015;1852(4):644&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">25149037</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin. 2014;32(3):629&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115580</ArticleId><ArticleId IdType="pubmed">25037082</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata H, Magran&#xe9; J, Kunst C, et al. Lysyl-tRNA synthetase is a target for mutant SOD1 toxicity in mitochondria. J Biol Chem. 2008;283(42):28321&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2568925</ArticleId><ArticleId IdType="pubmed">18715867</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Gulati S, Smoot E, et al. Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12(6):430&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446817</ArticleId><ArticleId IdType="pubmed">22023190</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>